Cyrus R. Kumana

Cyrus R. Kumana

Auto-generated profile, based on publicly available information

Cyrus R. Kumana

Department of Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong 999077, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LCLynn Chin
Lynn Chin
CKCyrus R. Kumana
Cyrus R. Kumana
YKYok Lam Kwong
Yok Lam Kwong
HGHarinder Gill
Harinder Gill
Appreciation of the properties of arsenic trioxide (ATO) has redefined the treatment landscape for acute promyelocytic leukaemia (APL) and offers promise as a treatment for numerous other diseases. The benefits of ATO in patients with APL is related to its ability to counteract the effects of PML::RARA, an oncoprotein that is invariably detected in the blood or bone marrow of affected individuals. The PML::RARA oncoprotein is degraded specifically by binding to ATO. Thus ATO, in combination with all-trans retinoic acid, has become the curative treatment for ATO. The multiple mechanisms of action of ATO has also paved the way for application in various condition encompassing autoimmune or inflammatory disorders, solid organ tumours, lymphomas and other subtypes of AML. The development of oral formulation of ATO (oral ATO) has reduced costs of treatment and improved treatment convenience allowing widespread applicability. In this review, we discuss the mechanisms of action of ATO, the development of oral ATO, and the applications of oral ATO in APL and other diseases.

3 March 2016 in Cardiovascular Therapeutics
Verified
Journal Article
Closed access
PDF file
CKCyrus R. Kumana
Cyrus R. Kumana
BCBernard M.Y. Cheung
Bernard M.Y. Cheung
DSDavid C.W. Siu
David C.W. Siu
HTHung-Fat Tse
Hung-Fat Tse
ILIan J. Lauder
Ian J. Lauder

22 April 2017 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
PDF file
CKCyrus R Kumana
Cyrus R Kumana
KTKathryn C B Tan
Kathryn C B Tan
BCBernard MY CHEUNG
Bernard MY CHEUNG
The modes of action and clinical implications of several of the newest classes of antidiabetic drugs used as monotherapy and as add-on therapy have been extensively reviewed in recent publications.1 2 Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (eg, empagliflozin) belong to one such novel class and act via interference with proximal renal tubular reabsorption of glucose; about 90% of such reabsorption depends on this cotransporter. They therefore reduce blood glucose concentrations, promote weight reduction and lower blood pressure through glycosuria and osmotic diuresis. Moreover, since their activity is independent of insulin, they are efficacious even in the presence of pancreatic beta cell failure, which is in marked contrast to many other antidiabetic drugs. Furthermore, polyuria and polydipsia are uncommon. Gliptins (eg, saxagliptin) form another new class of oral antidiabetic agents that reduce glucagon secretion but promote insulin release by interfering with the degradation of incretins (intestinal hormones produced in response to ingested meals), and are generally well tolerated. Glucagon-like-peptide 1 (GLP1) receptor agonists (eg, exenatide) are incretin mimetics that constitute yet another class of new antidiabetics and, together with SGLT2 inhibitors, are the only antidiabetic drugs that have a favourable weight loss effect. Subcutaneous administration and gastrointestinal side effects are distinct disadvantages. In contrast to many other antidiabetic agents, treatments with drugs in these three classes and metformin confer a lower risk of hypoglycaemia. Type 2 diabetes mellitus (T2DM) is more than just a disorder of glucose metabolism. Patients with T2DM die prematurely because of cardiovascular disease and renal failure. The goal of drug treatment of diabetes should therefore be more than just controlling the blood glucose. In the aftermath of the rosiglitazone controversy,3 …